Large-scale testing (Phase 3)Looking for participantsNCT06846671
What this trial is testing
Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Who this might be right for
CLLChronic Lymphocytic Leukemia
BeOne Medicines 250